Pharmaceutics_R&D
Follow
Find tag "Pharma"
3.7K views | +0 today
Pharmaceutics_R&D
Pharmaceutical companies R&D specifically in neuroscience, CNS disease, pain and electrophysiology
Your new post is loading...
Your new post is loading...
Scooped by Julien Hering, PhD
Scoop.it!

Research and development: Outsourcing trends

US contract research organizations are multiplying to meet drug-makers' outsourcing needs.

 

US drug-makers are outsourcing more and more of their research and development, mainly to contract research organizations, according to figures released in July by the US National Science Foundation (NSF). The shift could be good news for researchers seeking positions in industry. In 1991, pharmaceutical companies spent about US$800 million on external research and development, but that skyrocketed to $13 billion in 2011, says John Jankowski, head of research and development statistics at the NSF. That growth outstrips that of any other sector. In 1991, industrial extramural research spending totalled $3.3 billion, but by 2011, spending had risen to $25.3 billion for domestic companies alone. Pharmaceutical firms' share of that total was 23% in 1991, but ballooned to 51% by 2011. Jankowski says that much of the increase comes from the outsourcing of clinical trials. The number of US contract research organizations has risen to match the demand, from around 800 in 2000 to more than 3,100 by the end of 2011, according to the Tufts Center for the Study of Drug Development in Boston, Massachusetts. - Nature 512, 106, 06 August 2014

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

NIH's translational center scores first drug acquisition by pharma

NIH's translational center scores first drug acquisition by pharma | Pharmaceutics_R&D | Scoop.it

Agency says success of new molecule for sickle cell disease shows its drug development model is working.

For the first time, a drug being developed in part by a controversial new National Institutes of Health (NIH) center aimed at speeding drug development has been picked up by a major pharmaceutical company. Baxter International has acquired the biotech company developing Aes-103, a small molecule for treating sickle cell disease. (...) - By Jocelyn Kaiser, Science, 9 July 2014

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

SANOFI mise tout sur les vaccins

SANOFI mise tout sur les vaccins | Pharmaceutics_R&D | Scoop.it

Ses médicaments les plus profitables déjà ou sur le point de tomber dans le domaine public, le groupe français mise principalement sur 7 nouvelles plateformes de croissance et notamment sur les vaccins, la santé animale et les partenariats de recherche. (...) - par Maxime Michallet, Santé Publique & Santé Privée, 22 mars 2014

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

PharmaGossip: Lilly depression drug fails late-stage trial

Eli Lilly and Co on Thursday said its experimental drug to treat major depression failed to meet it primary goal in three late-stage trials and the drugmaker will not seek approval of the medicine for that condition.

The drug edivoxetine, a member of a family of medicines called norepinephrine reuptake inhibitors, was tested in combination with a member of a widely used class of depression treatments called selective serotonin reuptake inhibitors (SSRIs) in each of the three trials.

But after eight weeks of treatment, the combination of drugs that included edivoxetine did not prove superior to the SSRIs alone, thereby failing the main goal of the study. - PharmaGossip, December 5, 2013

more...
No comment yet.
Suggested by Magali Michel
Scoop.it!

"Dans l’industrie pharmaceutique, l'innovation génère un changement dans la proposition de valeur"

"Dans l’industrie pharmaceutique, l'innovation génère un changement dans la proposition de valeur" | Pharmaceutics_R&D | Scoop.it

Un rythme d’innovation accéléré, de nouveaux business models... L’industrie pharmaceutique n’est pas, comme les autres secteurs, épargné par la nécessité de s’adapter au renouveau technologique. (...) - par Quentin Capelle, L'Atelier Disruptive Innovation, 14 octobre 2013 

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Plombée en France, l’industrie pharmaceutique se lamente toujours

Plombée en France, l’industrie pharmaceutique se lamente toujours | Pharmaceutics_R&D | Scoop.it

En croissance grâce à ses exportations, l’industrie du médicament voit son marché français chuter. Et se dit victime des plans d’économies pour la sécurité sociale et de multiples taxes. Alors même qu’un député veut lui en imposer une nouvelle, pour la recherche dans le cancer des enfants… (...) - L'Usine Nouvelle, 14/06/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

European Court Wants Drug Data Kept Secret

 A court has ordered the European Medicines Agency (EMA) to keep data from two drug companies confidential, running counter to EMA's recent push to share clinical and nonclinical information as widely as possible. The temporary injunction from the General Court of the European Union backs two drug firms on the U.S. side of the pond: AbbVie, headquartered in North Chicago, Illinois, and InterMune in Brisbane, California. (...) - ScienceInsider, by Jennifer Couzin-Frankel on 30 April 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Influence Scores of the 24 Largest Biotech, Pharma, and Medtech Companies - Who’s the winner and how do you fare?

Influence Scores of the 24 Largest Biotech, Pharma, and Medtech Companies - Who’s the winner and how do you fare? | Pharmaceutics_R&D | Scoop.it

Which company takes the title? It may come as no surprise that pharma giant Pfizer claims the lead spot, however the sequence that follows shows interesting trends. In this article I’ll share bioscience companies with ideal digital presence and touch on available apps to score yours. The performance indictor was the Bio Web Score Absolute, a free tool measuring the digital presence of life science businesses. (...) - Biowebspin Public Place, by Sara Ahmadi, 26/04/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Why all pharmaceutical research should be made open access

Why all pharmaceutical research should be made open access | Pharmaceutics_R&D | Scoop.it

The government wants to make all publicly funded research available – but the same must be demanded of pharmas also

I recently had lunch with as staunch an advocate for open access as you'll ever meet (I won't name him, because it would be rude to attribute casual remarks to him without permission). We were talking about plans to mandate free and open publication of publicly funded scientific research. In the USA, there's the Federal Public Research Act, and in the UK, there's the coalition government's announcement that publicly funded research should be made available at no cost, under a Creative Commons licence that permits unlimited copying. (...) by Cory Doctorow, The Guardian, 20 november 2012

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation - GaBI Journal

The generic pharmaceutical industry: moving beyond incremental innovation towards re-innovation - GaBI Journal | Pharmaceutics_R&D | Scoop.it

Background: Due to the declining innovativeness of the classic R & D model in the original pharmaceutical industry, the generic pharmaceutical industry is aiming to become an innovation generator itself. 

Results: Those generic pharmaceutical firms that implement new competitive strategies have integrated re-innovation design into their product portfolio to provide more personalized, cost-effective products to meet the healthcare systems’, policymakers’ and patients’ demand for high quality accessible treatments. This re-orientation hopes to better face the changing competition challenges in both mature and developing markets. 
Conclusions: A new approach to innovativeness together with a value proposition strategy aims to deliver high quality products to patients.

(...) - by Barei F. et al., Generics and Biosimilars Initiative Journal (GaBI Journal). 2013;2(1)


more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

4 Key Drug Approvals Expected In The Next 30 Days

4 Key Drug Approvals Expected In The Next 30 Days | Pharmaceutics_R&D | Scoop.it

Biogen Idec's BG-12, United Therapeutics' oral Remodulin, Johnson & Johnson's Invokana and Allergan's Levadex are all nearing their possible launches

Investing in drug stocks isn't quite like investing in other stocks. While drugmakers' shares can move on earnings and buyout news like anyone else's, what really gets investors excited is an FDA decision allowing a new drug on the market. Here are some of the most important drugs awaiting approval in the next month. (...) - by Amy Reeves, Investors.com, 03/15/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Legendary Drug Industry Executives Warn U.S. Science Cuts Endanger The Future - Forbes

Legendary Drug Industry Executives Warn U.S. Science Cuts Endanger The Future - Forbes | Pharmaceutics_R&D | Scoop.it

Biomedical research and innovation are crucial to improving America’s health, global competitiveness, and economic growth, as both President Obama and House Majority Leader Cantor have stressed in recent weeks. In the wake of the sequester, and as the President and Congress move ahead with budget negotiations, now is the time for both parties to translate into action their bipartisan commitment to our nation’s science investment by restoring the budgets of the National Institutes of Health (NIH) and other science agencies that support basic biomedical research in universities and medical schools in all 50 states – an area of federal spending that is highly productive and a critical investment. (...) - by Marc Tessier-Lavigne, President, The Rockefeller University and former Chief Scientific Officer, Genentech Inc. (left); P. Roy Vagelos, Chairman, Regeneron Pharmaceuticals, and Retired Chairman and CEO, Merck & Co., Inc. (center); and Elias ZerhouniPresident R&D Sanofi and former Director of the National Institutes of Health., Forbes, 03/06/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Alltrials contd. - UCB warns of data ‘voyeurism’

Alltrials contd. - UCB warns of data ‘voyeurism’ | Pharmaceutics_R&D | Scoop.it
UCB chief executive Roch Doliveux has attacked the idea of making all clinical trial data publicly available, saying it could be ‘dangerous and misleading’. (...) - by Adam Hill, Pharmafile via PharmaGossip, 27/02/2013
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Biotech reels over patent ruling

Biotech reels over patent ruling | Pharmaceutics_R&D | Scoop.it

Firms fight for the right to patent natural products and processes. 

 

Guidelines that forbid patents on a wide array of natural products, phenomena and principles have many in the biotechnology and pharmaceutical industries worried about the future of their business. (...) - by Erika Check-Hayden, Nature, 08 July 2014

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

The biotech industry with Rob Carlson

The biotech industry with Rob Carlson | Pharmaceutics_R&D | Scoop.it
In this interview, I speak to Dr. Rob Carlson, a Principal at Biodesic, an engineering and strategic consulting firm in Seattle that provides services to governments and corporations around the globe. At the broadest level, Dr. Carlson is interested in the future role of biology as a human technology. He is the author of the book Biology is Technology: The Promise, Peril, and New Business of Engineering Life, published in 2010 by Harvard University Press; it received the PROSE award for the Best Engineering and Technology Book of 2010 and was named to the Best Books of 2010 lists by writers at both The Economist and ForeignPolicy.com. Carlson is a frequent international speaker and has served as an advisor to such diverse organisations as The Hastings Center, the PICNIC Design Festival, the UN, the OECD, the US Government, and companies ranging in size from start-ups to members of the Fortune 100. Carlson earned a doctorate in Physics from Princeton University in 1997. (...) - by Julie Gould, Nature Jobs Blog, 18 April 2014
more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Le groupe pharmaceutique GSK s'impose des pratiques plus éthiques

Le groupe pharmaceutique GSK s'impose des pratiques plus éthiques | Pharmaceutics_R&D | Scoop.it

Le britannique cesse de rémunérer les médecins pour la promotion de ses produits.
L'industrie pharmaceutique serait-elle prête à faire sa révolution culturelle ? En réformant ses pratiques commerciales, le britannique GSK donne en tout cas un signal dans ce sens. (...) - par Catherine Ducruet, Les Echos, 18/12/2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Novartis reboots brain division

Novartis reboots brain division | Pharmaceutics_R&D | Scoop.it
After years in the doldrums, research into neurological disorders is about to undergo a major change of direction.

In a sign that psychiatric-disease research is entering a new era, the pharmaceutical giant Novartis has hired an expert in neural circuitry, rather than pharmacology, to head its relaunched neuroscience division. (...) - by Alison Abbot, Nature, 08 October 2013

more...
Magdalena Kawalec's curator insight, November 25, 2013 7:01 AM

Good decission. Befor to decide "how to design it" maybe better to know "how it works in the first place"

Scooped by Julien Hering, PhD
Scoop.it!

Advertisements impact the physiological efficacy of a branded drug

We conducted randomized clinical trials to examine the impact of direct-to-consumer advertisements on the efficacy of a branded drug. We compared the objectively measured, physiological effect of Claritin (Merck & Co.), a leading antihistamine medication, across subjects randomized to watch a movie spliced with advertisements for Claritin or advertisements for Zyrtec (McNeil), a competitor antihistamine. Among subjects who test negative for common allergies, exposure to Claritin advertisements rather than Zyrtec advertisements increases the efficacy of Claritin. We conclude that branded drugs can interact with exposure to television advertisements. (...) - by Kamenica E et al., PNAS August 6, 2013 vol. 110 no. 32 12931-12935

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Does pharma spend more on marketing than R&D? A numbers check

Does pharma spend more on marketing than R&D? A numbers check | Pharmaceutics_R&D | Scoop.it

So, do drug companies really spend more money on marketing than on R&D? In the Pipeline takes a look at that contention, and the cold hard facts are these: Probably not. But it's hard to tell for sure.

Derek Lowe's blog dug up the numbers and calculated spending as a percentage of revenue. In the case of R&D, that's pretty easy to determine; companies break that number out as its own line item. As for marketing, sales expenses are lumped into a category dubbed SG&A, or sales, general and administrative expenses. And as Lowe notes, that category includes lots more than sales spending. Executive salaries, for instance. (...) - by Tracy Staton, FiercePharma, May 21, 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Target identification and mechanism of action in chemical biology and drug discovery

Target identification and mechanism of action in chemical biology and drug discovery | Pharmaceutics_R&D | Scoop.it

Target-identification and mechanism-of-action studies have important roles in small-molecule probe and drug discovery. Biological and technological advances have resulted in the increasing use of cell-based assays to discover new biologically active small molecules. Such studies allow small-molecule action to be tested in a more disease-relevant setting at the outset, but they require follow-up studies to determine the precise protein target or targets responsible for the observed phenotype. Target identification can be approached by direct biochemical methods, genetic interactions or computational inference. In many cases, however, combinations of approaches may be required to fully characterize on-target and off-target effects and to understand mechanisms of small-molecule action. (...) - by Schenone M et al., Nature Chemical Biology 9, 232–240 (2013)

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

L'irrésistible déclin de l’industrie pharmaceutique en France

L'irrésistible déclin de l’industrie pharmaceutique en France | Pharmaceutics_R&D | Scoop.it

Baisses de prix, impact des génériques : le marché du médicament devrait continuer de décliner cette année en France, selon une étude d’IMS Health. Une embellie serait possible en 2014, en fonction des décisions politiques.


Alors que les plans sociaux se poursuivent dans l’industrie pharmaceutique, les perspectives sur le marché français sont toujours sombres. Après avoir connu la première récession de son histoire en 2012, avec une chute de 2,3% en valeur, le marché des médicaments en ville devrait s’effondrer de 3,4% cette année, selon l’étude présentée ce mardi par le cabinet de conseil pour les acteurs de la santé IMS Health. (...) L'Usine Nouvelle, par Gaëlle Fleitour19 mars 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Drug-company data vaults to be opened

Drug-company data vaults to be opened | Pharmaceutics_R&D | Scoop.it

European agency will publish firms’ clinical-trial results.


International calls for the pharmaceutical industry to share the results of clinical trials have grown ever more intense amid revelations that high-profile companies have hidden crucial data on safety and efficacy. Now Europe is moving towards measures that would significantly increase disclosure of such data. (...) - by Daniel Cressey, Nature, 27 March 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s

US pharma: 465 drugs in R&D for chronic diseases affecting over-65s | Pharmaceutics_R&D | Scoop.it

US biopharmaceutical companies are currently developing 465 new medicines that target the 10 leading chronic conditions affecting people aged 65 and over, according to new industry data.

The medicines, which are all now in clinical trials or under review by the Food and Drug Administration (FDA), are diverse in scope, notes the Pharmaceutical Research and Manufacturers of America (PhRMA), which has published the data. (...) - by Lynne Taylor, PharmaTimes, March 22, 2013

more...
NCTC's curator insight, March 29, 2013 4:19 AM

Interesting, also in light of the Dutch IEMO project which aims at including seniors in clinical trials to measure the effect durgs have have on them.

Scooped by Julien Hering, PhD
Scoop.it!

Biomedical hiring : Naturejobs

Many drug-makers hope to recruit in next few years.


Many biopharmaceutical companies plan to hire scientists in the next three years, according to a report published on 4 February by the PwC Health Research Institute in Washington DC, part of London-based professional-services firm PwC. New Chemistry: Getting the Biopharmaceutical Talent Formula Right, which is based on surveys of company executives and recruiters, finds that 72% of drug-makers plan to boost their research capacity in the next 12 months by hiring scientists, creating partnerships or improving infrastructure. The results of the survey suggest that jobs will grow by about 30% among US medical scientists, biochemists and biophysicists by 2020. Responding companies want recruits who can develop and manage external partnerships, and who know about regulatory science, bioinformatics and outcomes research. Early-career scientists looking for opportunities need to “think about the entire value chain that leads to the development of a drug or medical device”, says Christopher Khoury, a senior manager at the Health Research Institute and lead author of the report. - Nature 494, 509 (2013), Published online 27 February 2013

more...
No comment yet.
Scooped by Julien Hering, PhD
Scoop.it!

Grünenthal et Ethypharm concluent un accord de licence dans le traitement de la douleur

Grünenthal et Ethypharm concluent un accord de licence dans le traitement de la douleur | Pharmaceutics_R&D | Scoop.it

Le groupe pharmaceutique allemand Grünenthal et Ethypharm, société française spécialisée dans les technologies de formulation innovantes, ont conclut un accord de licence, de distribution et d’approvisionnement exclusif. Cet accord permet à la société de commercialiser les comprimés sublinguaux à base de fentanyl d’Ethypharm pour le traitement des accès de douleur dus au cancer sur des marchés européens sélectionnés. (...) MyPharma Editions, 06/03/2013

more...
No comment yet.